| 1 |
32512672 | CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation | 2020 Dec 17 |
1 |
| 2 |
12130494 | Down-regulation of DNA repair in human CD34(+) progenitor cells corresponds to increased drug sensitivity and apoptotic response. | 2002 Aug 1 |
2 |
| 3 |
10800168 | Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. | 2000 May |
1 |
| 4 |
10037044 | The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. | 1999 Jan |
1 |
| 5 |
10583236 | Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. | 1999 Nov |
1 |
| 6 |
10634173 | CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. | 1999 Aug |
1 |
| 7 |
9692813 | Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. | 1998 Jun |
1 |
| 8 |
9827813 | Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. | 1998 Nov |
1 |
| 9 |
8932839 | Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. | 1996 Nov |
1 |